Tablet allergen immunotherapy: the anaphylaxis issue.
adults
allergen immunotherapy
anaphylactic reaction
children
safety
tablets
Journal
Allergologia et immunopathologia
ISSN: 1578-1267
Titre abrégé: Allergol Immunopathol (Madr)
Pays: Singapore
ID NLM: 0370073
Informations de publication
Date de publication:
2024
2024
Historique:
received:
06
09
2023
accepted:
21
11
2023
medline:
9
5
2024
pubmed:
9
5
2024
entrez:
9
5
2024
Statut:
epublish
Résumé
For the first time 15 years ago, tablet allergen immunotherapy (T-AIT) formulations were approved by regulatory agencies for treating allergic rhinitis caused by grass pollen in adults and children aged >5 years. Extensive evidences existed about effectiveness and safety of AIT. However, the safety profile is particularly compelling in children. Generally, T-AIT causes local reactions, mostly in the oral cavity, that are usually mild-to-moderate and often self-resolving. However, systemic allergic reactions are also observed with T-AIT, anaphylaxis representing the most fearsome adverse event, considering that it occurs in subjects treated for allergic rhinitis. Therefore, we conducted a literature search of patients reporting anaphylaxis because of T-AIT. Nine cases of anaphylactic reactions were reported in literature. Notably, no death was reported using T-AIT. This outcome was very important as it underscored the substantial safety of T-AIT. However, T-AIT deserves careful attention, mainly in the pediatric population. In this regard, after the first report of anaphylactic reaction at the first administration of T-AIT, manufacturers recommended that the first dose should be administered in a medical facility in the presence of staff with experience in managing anaphylaxis and the patient should be observed for at least 30 min. Interestingly, reported anaphylactic reactions were due to grass pollen extracts, with no report concerning other allergen extracts. However, it is relevant to note that anaphylactic reactions because of T-AIT are not reported in recent years.
Identifiants
pubmed: 38721958
doi: 10.15586/aei.v52i3.990
doi:
Substances chimiques
Allergens
0
Tablets
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
73-77Déclaration de conflit d'intérêts
The authors stated no conflict of interest.
Références
1. Głobińska A, Boonpiyathad T, Satitsuksanoa P, Kleuskens M, van de Veen W, Sokolowska M, et al. Mechanisms of allergen--specific immunotherapy: Diverse mechanisms of immune tolerance to allergens. Ann Allergy Asthma Immunol. 2018;121(3):306–12. 10.1016/j.anai.2018.06.026
doi: 10.1016/j.anai.2018.06.026
2. Calderon MA, Simons FER, Malling HJ, Lockey RF, Moingeon P, Demoly P. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile. Allergy. 2012;67(3):302–31. 10.1111/j.1398-9995.2011.02761.x
doi: 10.1111/j.1398-9995.2011.02761.x
3. Pfaar O, Bousquet J, Durham SR, Kleine-Tebbe J, Larché M, Roberts G, et al. One hundred and ten years of allergen immunotherapy: a journey from empiric observation to evidence. Allergy. 2022;77(2):454–68. 10.1111/all.15023
doi: 10.1111/all.15023
4. Tankersley M, Han JK, Nolte H. Clinical aspects of sublingual tablets and drops. Ann Allergy Asthma Immunol. 2020;124:573–82. 10.1016/j.anai.2019.12.025
doi: 10.1016/j.anai.2019.12.025
5. Muraro A, Worm M, Alviani C, Cardona V, DunnGalvin A, Garvey LH, et al. EAACI guidelines: anaphylaxis (2021 update). Allergy. 2022;77(2):357–77. 10.1111/all.15032
doi: 10.1111/all.15032
6. Turner PJ, Worm M, Ansotegui IJ, El-Gamal Y, Fernandez Rivas M, Fineman S, et al. Time to revisit the definition and clinical criteria for anaphylaxis? World Allergy Org J. 2019;12:100066. 10.1016/j.waojou.2019.100066
doi: 10.1016/j.waojou.2019.100066
7. Stafford A, Turner PJ. Grading the severity of anaphylaxis. Curr Opin Allergy Clin Immunol. 2023;23(3):218–25. 10.1097/ACI.0000000000000901
doi: 10.1097/ACI.0000000000000901
8. Ciprandi G, Tosca MA. LTP allergy: a pragmatic and reasonable approach in clinical practice. Eur Ann Allergy Clin Immunol. 2019;51(2):84–5. 10.23822/EurAnnACI.1764-1489.75
doi: 10.23822/EurAnnACI.1764-1489.75
9. Bilò MB, Martini M, Tontini C, Corsi A, Antonicelli L. Anaphylaxis. Eur Ann Allergy Clin Immunol. 2021;53(1):4–17. 10.23822/EurAnnACI.1764-1489.158
doi: 10.23822/EurAnnACI.1764-1489.158
10. Turner PJ, Arasi S, Ballmer-Weber B, Baseggio Conrado A, Deschildre A, Gerdts J, et al. Risk factors for severe reactions in food allergy: rapid evidence review with meta-analysis. Allergy. 2022;77(9):2634–52. 10.1111/all.15318
doi: 10.1111/all.15318
11. Motosue MS, Li JT, Campbell RL. Anaphylaxis: epidemiology and differential diagnosis. Immunol Allergy Clin North Am. 2022;42(1):13–25. 10.1016/j.iac.2021.09.010
doi: 10.1016/j.iac.2021.09.010
12. Gelardi M, Maselli Del Giudice A, Candreva T, Fiorella ML, Allen M, et al. Nasal resistance and allergic inflammation depend on allergen type. Int Arch Allergy Immunol. 2006;141(4):384–9. 10.1159/000095465
doi: 10.1159/000095465
13. Hsiao KC, Smart J. Anaphylaxis caused by in-season switchover of sublingual immunotherapy formulation. Pediatr Allergy Immunol. 2014 Nov;25(7):714–5. 10.1111/pai.12268
doi: 10.1111/pai.12268
14. Eberle P, Brueck H, Gall R, Hadler M, Sieber J, Karagiannis E. An observational, real-life safety study of a 5-grass pollen sublingual tablet in children and adolescents. Pediatr Allergy Immunol. 2014 Dec;25(8):760–6. 10.1111/pai.12298
doi: 10.1111/pai.12298
15. Didier A, Bons B. Safety and tolerability of 5-grass pollen tablet sublingual immunotherapy: pooled analysis and clinical review. Expert Opin Drug Saf. 2015 May;14(5):777-88. 10.1517/14740338.2015.1017468. Epub 2015 Mar 3. Erratum In: Expert Opin Drug Saf. 2015 Jul;14(7):1169. 25732009.
doi: 10.1517/14740338.2015.1017468
16. Blin P, Demoly P, Drouet M, Falissard B, Lignot-Maleyran S, Maizi H et al.; An observational cohort study of the use of five-grass-pollen extract sublingual immunotherapy during the 2015 pollen season in France. Allergy Asthma Clin Immunol. 2018 Sep 24;14:38. 10.1186/s13223-018-0262-9
doi: 10.1186/s13223-018-0262-9
17. Gerstlauer M, Szepfalusi Z, Golden D, Geng B, de Blic J. Real-life safety of 5-grass pollen tablet in 5-to-9-year-old children with allergic rhinoconjunctivitis. Ann Allergy Asthma Immunol. 2019 Jul;123(1):70–80. 10.1016/j.anai.2019.04.011
doi: 10.1016/j.anai.2019.04.011
18. de Groot H, Bijl A. Anaphylactic reaction after the first dose of sublingual immunotherapy with grass pollen tablet. Allergy. 2009 Jun;64(6):963–4. 10.1111/j.1398-9995.2009.01998.x. Epub 2009 Feb 16. 19222420.
doi: 10.1111/j.1398-9995.2009.01998.x
19. European Union Clinical Trials Register. 2009. A phase IIIB trial investigating 3-year treatment efficacy, tolerability and safety of Grazax in children aged 5-18 years with grass pollen induced rhinoconjunctivitis with/without controlled asthma (three consecutive pollen seasons treatment). Eudra CT number 2009-0149 23-22. Available from: https://www.clinicaltrialsregister.eu/ctrsearch/trial/2009-014923-22/results (Accessed on 24 May 2023).
20. Halken S, Roberts G, Valovirta E, Nolte H, Hulstrøm V, Blaiss MS. Safety of Timothy Grass Sublingual Immunotherapy Tablet in Children: Pooled Analyses of Clinical Trials. J Allergy Clin Immunol Pract. 2020 Apr;8(4):1387–1393.e2. 10.1016/j.jaip.2020.01.008
doi: 10.1016/j.jaip.2020.01.008
21. Bufe A, Eberle P, Franke-Beckmann E, Funck J, Kimmig M, Klimek L, Knecht R, Stephan V, Tholstrup B, Weisshaar C, Kaiser F. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol. 2009 Jan;123(1):167–173.e7. 10.1016/j.jaci.2008.10.044
doi: 10.1016/j.jaci.2008.10.044
22. Blaiss M, Maloney J, Nolte H, Gawchik S, Yao R, Skoner DP. Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents. J Allergy Clin Immunol. 2011 Jan;127(1):64–71, 71.e1–4. 10.1016/j.jaci.2010.11.034
doi: 10.1016/j.jaci.2010.11.034
23. Murphy K, Gawchik S, Bernstein D, Andersen J, Pedersen MR. A phase 3 trial assessing the efficacy and safety of grass allergy immunotherapy tablet in subjects with grass pollen--induced allergic rhinitis with or without conjunctivitis, with or without asthma. J Negat Results Biomed. 2013 Jun 1;12:10. 10.1186/1477-5751-12-10. 23725348; PMC3689082.
doi: 10.1186/1477-5751-12-10
24. Schwab JA, Wolf H, Schnitker J, Wüstenberg E. Safety and tolerability of an intra-seasonal initiation of the SQ-standardised grass allergy immunotherapy tablet: a non-interventional observational study investigating the feasibility during routine administration. Clin Drug Investig. 2013 Oct;33(10):719–26. 10.1007/s40261-013-0115-8
doi: 10.1007/s40261-013-0115-8
25. Reiber R, Wolf H, Futschik T, Schwab JA, Hölscher U, Schnitker J et al.; Safety and tolerability of the standardized quality house dust mite sublingual immunotherapy tablet in real life: A noninterventional, open-label study. J Allergy Clin Immunol Pract. 2021 Aug;9(8):3221–3223.e5. 10.1016/j.jaip.2021.03.045
doi: 10.1016/j.jaip.2021.03.045